RPD.F ROYALTY PHARMA OA DL-0001
- Market cap
- EUR 35.1B
- P/E
- 46.3x
- P/B
- 4.45x
- ROE
- 8.9%
- Dividend yield
- 1.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RPD.F undervalued?
Graham numberThe Graham number of ROYALTY PHARMA OA DL-0001 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ROYALTY PHARMA OA DL-0001 fundamental analysis
No fundamental analysis for ROYALTY PHARMA OA DL-0001 yet.
ROYALTY PHARMA OA DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ROYALTY PHARMA OA DL-0001
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance t…
Full company profileROYALTY PHARMA OA DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ROYALTY PHARMA OA DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.24B | 2.35B | 2.26B | 2.38B | 2.66B |
| Operating Income | 923M | 1.49B | 1.29B | 1.56B | 1.77B |
| EBITDA | 424M | 1.89B | 1.56B | 1.64B | 1.46B |
| Net Income | 42.8M | 1.13B | 859M | 771M | 610M |
| EPS | 0.10 | 2.54 | 1.93 | 1.80 | 1.37 |
| Balance Sheet | |||||
| Total Assets | 16.8B | 16.4B | 18.2B | 19.6B | 19.5B |
| Total Liabilities | 7.29B | 6.30B | 7.88B | 9.91B | 9.67B |
| Shareholders' Equity | 5.63B | 6.53B | 6.95B | 6.48B | 6.84B |
| Cash & Short-term Investments | 1.71B | 477M | 929M | 619M | 514M |
| Cash Flow | |||||
| Operating Cash Flow | 2.14B | 2.99B | 2.77B | 2.49B | 2.84B |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 2.14B | 2.99B | 2.77B | 2.49B | 2.84B |
| Ratios | |||||
| ROE | 0.8% | 17.4% | 12.4% | 11.9% | 8.9% |
| ROA | 0.3% | 6.9% | 4.7% | 3.9% | 3.1% |
| Net Profit Margin | 1.9% | 48.2% | 37.9% | 32.4% | 22.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ROYALTY PHARMA OA DL-0001 dividends
- Dividend yield
- 1.39%
- Forward dividend
- 0.84 EUR
- Payout ratio
- 49.1%
- Ex-dividend date
- Nov 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 378M | 0.88 | 49.1% |
| 2024 | USD 376M | 0.84 | 43.8% |
| 2023 | USD 358M | 0.80 | 31.6% |
| 2022 | USD 333M | 0.75 | 778.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns ROYALTY PHARMA OA DL-0001
- Insiders 6.50%
- Institutions 88.22%
- Public & others 5.28%
- Shares outstanding 445M
- Free float 417M
ROYALTY PHARMA OA DL-0001 company profile
- Company name
- ROYALTY PHARMA OA DL-0001
- Ticker
- RPD.F
- ISIN
- GB00BMVP7Y09
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- December
- Address
- 110 East 59th Street, New York, NY, United States, 10022
- Phone
- 212 883 0200
- Website
- royaltypharma.com
About ROYALTY PHARMA OA DL-0001
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
ROYALTY PHARMA OA DL-0001 management
10- Mr. Pablo LegorretaFounder, Chairman of the Board & CEO · born 1963
- Mr. Terrance P. CoyneExecutive VP & CFO
- Mr. Christopher HiteChairman of Partnering & Investments · born 1967
- Dr. Marshall Jonathan Urist M.D., Ph.D.Head of Research & Investments · born 1976
- Mr. Greg ButzExecutive Vice President of Partnering & Investments
- Mr. Eric Cornelius SchneiderSenior VP & Chief Technology Officer
- Dr. James Folmar Reddoch Ph.D.Executive VP of Investments & Chief Scientific Officer · born 1970
- Mr. George Grofik C.F.A., CPASenior VP and Head of Investor Relations & Communications
- Mr. Arthur Richard McGivern J.D.Executive VP of Investment & Chief Legal Officer · born 1975
- Ms. Molly SawayaExecutive VP & Head of Human Capital